Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
Authors
Keywords
Alirocumab, Ezetimibe, Low-density lipoprotein cholesterol, Monoclonal antibody, Proprotein convertase subtilisin kexin type 9
Journal
BMC Cardiovascular Disorders
Volume 14, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-09-21
DOI
10.1186/1471-2261-14-121
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel
- (2014) Todd J. Anderson et al. CANADIAN JOURNAL OF CARDIOLOGY
- Intermittent Nondaily Dosing Strategies in Patients with Previous Statin-Induced Myopathy
- (2013) Alyssa J Keating et al. ANNALS OF PHARMACOTHERAPY
- 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
- (2013) Todd J. Anderson et al. CANADIAN JOURNAL OF CARDIOLOGY
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. CIRCULATION
- Executive Summary: Heart Disease and Stroke Statistics—2013 Update
- (2013) Alan S. Go et al. CIRCULATION
- PCSK9 inhibitors
- (2013) Michel Farnier CURRENT OPINION IN LIPIDOLOGY
- Alirocumab, a Fully Human Monoclonal Antibody to Proprotein Convertase Subtilisin/kexin Type 9: Therapeutic Dosing in Phase 3 Studies
- (2013) Robert Pordy et al. Journal of Clinical Lipidology
- Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease
- (2013) Peter P. Toth et al. Journal of Clinical Lipidology
- Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey
- (2013) Ko-Fan Wang et al. Journal of the Chinese Medical Association
- First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients
- (2013) Ioanna Xanthopoulou et al. Lipids in Health and Disease
- Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis
- (2013) Peter H. Jones et al. Journal of the American Heart Association
- Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials
- (2012) Doralisa Morrone et al. ATHEROSCLEROSIS
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Statins for people at low risk of cardiovascular disease – Authors' reply
- (2012) Borislava Mihaylova et al. LANCET
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- (2012) Evan A Stein et al. LANCET
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical aspects of PCSK9
- (2011) Bertrand Cariou et al. ATHEROSCLEROSIS
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study
- (2011) J. R. Banegas et al. EUROPEAN HEART JOURNAL
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Treating statin-intolerant patients
- (2011) Marcello Arca et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany
- (2010) Anselm K. Gitt et al. Clinical Research in Cardiology
- High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
- (2010) Greg Welder et al. JOURNAL OF LIPID RESEARCH
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries
- (2009) Michel P. Hermans et al. CURRENT MEDICAL RESEARCH AND OPINION
- MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets
- (2009) Ohidul Siddiqui et al. Journal of Biopharmaceutical Statistics
- Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries
- (2009) Kornelia Kotseva et al. LANCET
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started